GenScript Signs an Agreement with Selecxine to Develop Therapies for Immuno-Oncology

GenScript Signs an Agreement with Selecxine to Develop Therapies for Immuno-Oncology

Shots:

  • GenScript will be responsible for all pre-clinical pharmacy research and IND filling in Selecxine’s project which is based on cytokine-antibody complexes
  • The company provided development solutions in different hosts tailored to customers and provided the preparation and purification solutions for the final complex,; further the project will test and enhance the process development capability of GenScript CDMO team
  • SLC-3010 is a complex of IL-2 and anti-human IL-2 antibody (TCB2) that selectively stimulates the anti-tumor immune response and its efficacy for the removal of various types of tumor was thoroughly demonstrated through various in vitro and in vivo experiments  

Click here to read full press release/ article | Ref: PRNewswire | Image: Behance